Hidradentitis Suppurativa

Latest News

Phase 3 Data for Bimekizumab Shows Well Maintained Response
Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

Creative glowing blue breaking news pattern background with globe. Headline, communication and global world concept. 3D Rendering.credit:  ©Who is Danny - Adobestock
New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023

Hadar Lev-Tov, MD
Dermatologist Talks About the ABCs of Wounds and HS Support at Annual Meeting

March 17th 2023

Hidradenitis Suppurativa Factors Affecting Patient Quality of Life
Hidradenitis Suppurativa Factors Affecting Patient Quality of Life

March 8th 2023

Hidradenitis Suppurativa Linked to Atopic Diseases
Hidradenitis Suppurativa Linked to Atopic Diseases

March 7th 2023

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.